

Customer No. 20462
Attorney Docket No. P33071
Confirmation No.: 6798

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Axten *et al.* September 3, 2008
Serial No.: 10/518,655 Group Art Unit: 1624
Filed: July 14, 2005 Examiner: K. Habte
For: COMPOUNDS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450
Attorney Docket No. P33071

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37C.F.R. §1.97(c)

The attached list of citations on PTO Form 1449 is being submitted under the provisions of 37 CFR §1.56 and §1.97 for consideration by the United States Patent and Trademark Office, prior to the granting of this patent. Their inclusion herein should not, however, be construed as an admission that any particular cited document is effective prior art or that it discloses or renders obvious any aspect of the claimed invention. A copy of each cited document is enclosed, except U.S. Patent documents, and those references which are already part of the filewrapper.

The documents cited herein are listed on the enclosed PTO Form 1449. A copy of each cited document is enclosed, except U.S. Patent documents, and those references which are already part of the filewrapper.

Some of the cited foreign patent documents are in a non-English language. Applicants note that these foreign patent documents have English language family members, including the patent documents shown below:

Foreign Patent Document:	An English language family member*:
WO01/25227A2	US 6,403,610 B1
WO01/37826	US 6,699,891 B1
WO01/44191	US 7,115,634 B2
WO01/53288	US 6,784,192 B2
WO02/40474A2	US 6,603,005 B2
WO02/072572	US 6,602,884 B2
WO04/011454A2	US 6,806,277 B2

Serial No.: 11/814,611
Group Art Unit No.: 1624

Foreign Patent Document:	An English language family member*:
WO04/024712	US 7,232,834 B2
WO04/024713A1	US 6,841,562 B2
WO04/035569	US 7,223,776 B2
WO04/060886	US 6,939,970 B2
WO04/087647	US 7,232,833 B2
WO04/089947	US 2006-205719 A1
EP 0532456	US 5,310,743A

* These documents are also listed in the enclosed form PTO 1449

In addition, an English language abstract for FR 2815031 is being provided herewith (Derwent 2002-397066/43).

This information disclosure statement is being filed under the provisions of 37 C.F.R. §1.97(c)(2), i.e., **after** three months of the filing date of the subject application or after the mailing date of the first Office Action on the merits, whichever event occurred last but **before** the mailing date of a either a Final Action under 37 CFR §1.113, a Notice of Allowance under 37 CFR §1.311, or an action that otherwise closes prosecution, along with authorization to charge the \$180.00 fee specified in 37 C.F.R. §1.17(p) to the Deposit Account No. 19-2570.

Please charge any additional fees under 37 C.F.R. §1.16 or §1.17 which may be required by this paper, or credit any overpayment, to the indicated Deposit Account.

Respectfully submitted,



Loretta J. Sauermelch
Attorney for Applicants
Registration No. 37,347

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Tel: (610) 270-6854; Fax: (610) 270-5090
n:\Loretta\Applications\IP3s\IP33071\SuppIDS-1.doc